Abuse-deterrent opioid formulations: are they a pipe dream?
Abuse-deterrent opioid formulations: are they a pipe dream?
复制标题
DOI：
10.1007/s11926-008-0003-z
复制
发表时间：
2008-01-01
影响因子：
5
通讯作者：
Katz, Nathaniel
中科院分区：
文献类型：
--
作者：
Katz, Nathaniel
对阿片类药物治疗疼痛的持续需求及其与滥用和成瘾的不可避免的联系，导致需要采取风险缓解方法，以优化其风险效益比。滥用威慑制剂（ADF）已成为一种支持阿片类药物获得的手段，同时限制滥用及其后果。出现了几种不同类型的ADF，包括篡改的物理屏障、激动剂-拮抗剂制剂、厌恶、前药和替代给药方法。每种类型都有可能减少特定形式的处方阿片类药物滥用。ADF有可能减少处方阿片类药物滥用的公共卫生负担，但它们不仅需要技术上成功的制剂，还需要适当的科学评估，广泛的市场渗透以及对其益处的合理预期。
The continued need for opioids to treat pain and their unavoidable link to abuse and addiction create a need for risk mitigation approaches that optimize their risk-benefit ratio. Abuse-deterrent formulations (ADFs) have emerged as a means for supporting opioid access while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist-antagonist formulations, aversion, prodrugs, and alternative methods of administration. Each of these types has the potential to reduce specific forms of prescription opioid abuse. ADFs have the potential to reduce the public health burden of prescription opioid abuse, but they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.